Literature DB >> 12623635

Sequential pathological and immunologic analysis of percutaneous microwave coagulation therapy of hepatocellular carcinoma.

B W Dong1, J Zhang, P Liang, X L Yu, L Su, D J Yu, X L Ji, G Yu.   

Abstract

PURPOSE: To evaluate sequential pathologic and immunologic changes and their prognostic significance after percutaneous microwave coagulation therapy (PMCT) of hepatocellular carcinoma (HCC).
METHODS: Eighty-nine nodules in 82 consecutive patients were studied. The 89 nodules were divided into two groups: a treatment group, with 82 primary nodules (average dimension was 3.4 +/- 1.2 cm) in 82 patients, and a control group, of seven nodules (average dimension was 1.4 +/- 0.6 cm) in seven patients. The criteria for a nodule's inclusion in the control group was that the nodule was one of two nodules in the same patient and that the two nodules were located in different liver lobes. This guarantees that while one nodule is treated by PMCT, the distant one will not be directly affected by the microwave thermal field. The control group nodules were treated after the study was completed. Specimens were taken with ultrasound-guided liver biopsy from the treated nodule and the control nodule, pre- and post-PMCT. Infiltration by T-lymphocytes, B-lymphocytes, NK cells and macrophages in the tumour tissue were observed immunohistochemically using a panel of monoclonal antibodies against CD3, CD45RO, CD20, CD56 and CD68. The extent of immune cell infiltration was compared both before and after PMCT, as well as between the treated and control nodules. The relationship between the prognosis and the extent of immunocyte infiltration was analysed.
RESULTS: The patients were followed for 2-26 months (mean 14.6 +/- 6.3) post-treatment. The recurrence rates at 1 and 2 years were 20.4% and 28.1% within the liver in treatment group, respectively. The survival rates at 1 and 2 years were 92.5% and 75.3% for the treatment group. T-cells, NK cells and macrophages increased significantly in both treated and untreated nodules after PMCT, albeit less markedly within untreated nodules when compared to the treated ones. There is a statistically significant correlation between survival outcome and the extent of immunocyte infiltration.
CONCLUSIONS: For inoperable HCC patients, PMCT is one of the treatment choices shown to be effective. Apart from its tissue coagulation effect, an increased systemic immune response directed against the tumour may also play an important role in improved survival.

Entities:  

Mesh:

Year:  2003        PMID: 12623635     DOI: 10.1080/0265673021000017154

Source DB:  PubMed          Journal:  Int J Hyperthermia        ISSN: 0265-6736            Impact factor:   3.914


  14 in total

Review 1.  Thermal ablation of tumours: biological mechanisms and advances in therapy.

Authors:  Katrina F Chu; Damian E Dupuy
Journal:  Nat Rev Cancer       Date:  2014-03       Impact factor: 60.716

2.  Pure transcatheter arterial chemoembolization therapy for intrahepatic tumors causes a shrink in pulmonary metastases of hepatocellular carcinoma.

Authors:  Huiyong Wu; Wei Zhao; Shuguang Liu; Jinsong Zheng; Guanglei Ji; Yinfa Xie
Journal:  Int J Clin Exp Med       Date:  2015-01-15

Review 3.  Harnessing the immunomodulatory effect of thermal and non-thermal ablative therapies for cancer treatment.

Authors:  Christopher Bastianpillai; Neophytos Petrides; Taimur Shah; Stephanie Guillaumier; Hashim U Ahmed; Manit Arya
Journal:  Tumour Biol       Date:  2015-09-30

4.  Construction and clinical significance of a predictive system for prognosis of hepatocellular carcinoma.

Authors:  Jun Cui; Bao-Wei Dong; Ping Liang; Xiao-Ling Yu; De-Jiang Yu
Journal:  World J Gastroenterol       Date:  2005-05-28       Impact factor: 5.742

Review 5.  Recent Advances in Tumor Ablation for Hepatocellular Carcinoma.

Authors:  Tae Wook Kang; Hyunchul Rhim
Journal:  Liver Cancer       Date:  2015-07-17       Impact factor: 11.740

6.  Combined use of microwave ablation and cell immunotherapy induces nonspecific immunity of hepatocellular carcinoma model mice.

Authors:  Xuhua Duan; Manzhou Wang; Xinwei Han; Jianzhuang Ren; Guohao Huang; Shuguang Ju; Qinghui Zhang
Journal:  Cell Cycle       Date:  2020-12-07       Impact factor: 4.534

Review 7.  More than just tumor destruction: immunomodulation by thermal ablation of cancer.

Authors:  Sebastian P Haen; Philippe L Pereira; Helmut R Salih; Hans-Georg Rammensee; Cécile Gouttefangeas
Journal:  Clin Dev Immunol       Date:  2011-12-29

8.  Microwave ablation combined with OK-432 induces Th1-type response and specific antitumor immunity in a murine model of breast cancer.

Authors:  Li Li; Wei Wang; Hong Pan; Ge Ma; Xinyi Shi; Hui Xie; Xiaoan Liu; Qiang Ding; Wenbin Zhou; Shui Wang
Journal:  J Transl Med       Date:  2017-01-31       Impact factor: 5.531

Review 9.  Local Destruction of Tumors and Systemic Immune Effects.

Authors:  Karl-Göran Tranberg
Journal:  Front Oncol       Date:  2021-07-08       Impact factor: 6.244

10.  Screening for immune-potentiating antigens from hepatocellular carcinoma patients after radiofrequency ablation by serum proteomic analysis.

Authors:  Shunli Shen; Hong Peng; Ye Wang; Ming Xu; Manxia Lin; Xiaoyan Xie; Baogang Peng; Ming Kuang
Journal:  BMC Cancer       Date:  2018-01-31       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.